Inozyme Historical Financial Ratios

INZY Stock

USD 1.46 0.04 2.82%

Inozyme Pharma is lately reporting on over 96 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 1.49 or Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Inozyme Pharma financial condition quickly.

Quick Ratio Current Ratio

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inozyme Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Inozyme Stock please use our How to Invest in Inozyme Pharma guide.

About Inozyme Financial Ratios Analysis

Inozyme PharmaFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Inozyme Pharma investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Inozyme financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Inozyme Pharma history.

Inozyme Pharma Financial Ratios Chart

At this time, Inozyme Pharma's Price Earnings To Growth Ratio is fairly stable compared to the past year.

Payables Turnover Cash Per Share Days Payables Outstanding Income Quality

Add Fundamental

Payables Turnover

A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.

Income Quality

An assessment of the sustainability of a company's earnings over time, considering factors like revenue source diversification and cost structure.

Most ratios from Inozyme Pharma's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Inozyme Pharma current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inozyme Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Inozyme Stock please use our How to Invest in Inozyme Pharma guide.At this time, Inozyme Pharma's Price Earnings To Growth Ratio is fairly stable compared to the past year.

Inozyme Pharma fundamentals Correlations

	Ptb Ratio	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow	Pe Ratio	Return On Tangible Assets	Ev To Free Cash Flow	Earnings Yield	Net Debt To E B I T D A
Ptb Ratio		0.85	-0.57	-0.96	-0.97	1.0	-0.96	0.19	-0.8	-0.95	0.82	0.77	0.61	0.96	0.44	0.94	0.96	-0.97	-0.9	-0.95	0.98	0.99	-0.94	0.98	-0.57	-0.87
Book Value Per Share	0.85		-0.45	-0.82	-0.72	0.85	-0.82	0.3	-0.63	-0.91	0.62	0.5	0.8	0.73	0.23	0.62	0.73	-0.71	-0.84	-0.87	0.77	0.78	-0.69	0.77	-0.46	-0.56
Free Cash Flow Yield	-0.57	-0.45		0.54	0.59	-0.57	0.54	0.46	0.6	0.49	-0.7	-0.47	-0.03	-0.69	-0.17	-0.58	-0.69	0.62	0.5	0.65	-0.68	-0.64	0.67	-0.69	1.0	0.63
Operating Cash Flow Per Share	-0.96	-0.82	0.54		0.95	-0.96	1.0	-0.04	0.86	0.97	-0.82	-0.7	-0.54	-0.95	-0.41	-0.91	-0.95	0.95	0.88	0.91	-0.96	-0.96	0.96	-0.96	0.55	0.86
Capex To Depreciation	-0.97	-0.72	0.59	0.95		-0.97	0.95	-0.1	0.81	0.89	-0.83	-0.78	-0.45	-0.98	-0.45	-0.99	-0.98	1.0	0.87	0.89	-0.98	-0.99	0.98	-0.98	0.59	0.92
Pb Ratio	1.0	0.85	-0.57	-0.96	-0.97		-0.96	0.19	-0.8	-0.95	0.82	0.77	0.61	0.96	0.44	0.94	0.96	-0.97	-0.9	-0.95	0.98	0.99	-0.94	0.98	-0.57	-0.87
Free Cash Flow Per Share	-0.96	-0.82	0.54	1.0	0.95	-0.96		-0.04	0.85	0.97	-0.82	-0.69	-0.54	-0.94	-0.41	-0.91	-0.94	0.95	0.89	0.91	-0.95	-0.96	0.96	-0.95	0.54	0.86
Roic	0.19	0.3	0.46	-0.04	-0.1	0.19	-0.04		0.31	-0.2	-0.28	-0.04	0.64	-0.03	-0.13	0.04	-0.03	-0.04	-0.33	-0.02	0.01	0.08	0.07	0.01	0.45	0.15
Inventory Turnover	-0.8	-0.63	0.6	0.86	0.81	-0.8	0.85	0.31		0.72	-0.97	-0.84	-0.14	-0.89	-0.5	-0.82	-0.89	0.85	0.55	0.88	-0.87	-0.83	0.83	-0.87	0.59	0.92
Net Income Per Share	-0.95	-0.91	0.49	0.97	0.89	-0.95	0.97	-0.2	0.72		-0.68	-0.56	-0.72	-0.87	-0.3	-0.82	-0.87	0.88	0.95	0.87	-0.9	-0.92	0.89	-0.9	0.5	0.72
Days Of Inventory On Hand	0.82	0.62	-0.7	-0.82	-0.83	0.82	-0.82	-0.28	-0.97	-0.68		0.91	0.12	0.92	0.54	0.85	0.92	-0.88	-0.55	-0.91	0.9	0.86	-0.84	0.9	-0.68	-0.96
Payables Turnover	0.77	0.5	-0.47	-0.7	-0.78	0.77	-0.69	-0.04	-0.84	-0.56	0.91		0.15	0.84	0.67	0.84	0.84	-0.82	-0.44	-0.83	0.81	0.79	-0.72	0.82	-0.44	-0.92
Cash Per Share	0.61	0.8	-0.03	-0.54	-0.45	0.61	-0.54	0.64	-0.14	-0.72	0.12	0.15		0.38	0.12	0.33	0.38	-0.41	-0.74	-0.51	0.44	0.49	-0.39	0.44	-0.05	-0.15
Pocfratio	0.96	0.73	-0.69	-0.95	-0.98	0.96	-0.94	-0.03	-0.89	-0.87	0.92	0.84	0.38		0.48	0.97	1.0	-0.99	-0.81	-0.94	1.0	0.99	-0.97	1.0	-0.68	-0.96
Interest Coverage	0.44	0.23	-0.17	-0.41	-0.45	0.44	-0.41	-0.13	-0.5	-0.3	0.54	0.67	0.12	0.48		0.51	0.48	-0.48	-0.1	-0.51	0.46	0.45	-0.43	0.46	-0.14	-0.57
Capex To Operating Cash Flow	0.94	0.62	-0.58	-0.91	-0.99	0.94	-0.91	0.04	-0.82	-0.82	0.85	0.84	0.33	0.97	0.51		0.97	-0.99	-0.78	-0.86	0.97	0.97	-0.96	0.97	-0.57	-0.96
Pfcf Ratio	0.96	0.73	-0.69	-0.95	-0.98	0.96	-0.94	-0.03	-0.89	-0.87	0.92	0.84	0.38	1.0	0.48	0.97		-0.99	-0.81	-0.94	1.0	0.99	-0.97	1.0	-0.68	-0.96
Days Payables Outstanding	-0.97	-0.71	0.62	0.95	1.0	-0.97	0.95	-0.04	0.85	0.88	-0.88	-0.82	-0.41	-0.99	-0.48	-0.99	-0.99		0.83	0.91	-0.99	-0.99	0.98	-0.99	0.61	0.95
Income Quality	-0.9	-0.84	0.5	0.88	0.87	-0.9	0.89	-0.33	0.55	0.95	-0.55	-0.44	-0.74	-0.81	-0.1	-0.78	-0.81	0.83		0.77	-0.84	-0.88	0.85	-0.84	0.51	0.63
Roe	-0.95	-0.87	0.65	0.91	0.89	-0.95	0.91	-0.02	0.88	0.87	-0.91	-0.83	-0.51	-0.94	-0.51	-0.86	-0.94	0.91	0.77		-0.95	-0.93	0.87	-0.95	0.64	0.87
Ev To Operating Cash Flow	0.98	0.77	-0.68	-0.96	-0.98	0.98	-0.95	0.01	-0.87	-0.9	0.9	0.81	0.44	1.0	0.46	0.97	1.0	-0.99	-0.84	-0.95		1.0	-0.97	1.0	-0.68	-0.94
Pe Ratio	0.99	0.78	-0.64	-0.96	-0.99	0.99	-0.96	0.08	-0.83	-0.92	0.86	0.79	0.49	0.99	0.45	0.97	0.99	-0.99	-0.88	-0.93	1.0		-0.98	1.0	-0.63	-0.92
Return On Tangible Assets	-0.94	-0.69	0.67	0.96	0.98	-0.94	0.96	0.07	0.83	0.89	-0.84	-0.72	-0.39	-0.97	-0.43	-0.96	-0.97	0.98	0.85	0.87	-0.97	-0.98		-0.97	0.67	0.91
Ev To Free Cash Flow	0.98	0.77	-0.69	-0.96	-0.98	0.98	-0.95	0.01	-0.87	-0.9	0.9	0.82	0.44	1.0	0.46	0.97	1.0	-0.99	-0.84	-0.95	1.0	1.0	-0.97		-0.68	-0.94
Earnings Yield	-0.57	-0.46	1.0	0.55	0.59	-0.57	0.54	0.45	0.59	0.5	-0.68	-0.44	-0.05	-0.68	-0.14	-0.57	-0.68	0.61	0.51	0.64	-0.68	-0.63	0.67	-0.68		0.61
Net Debt To E B I T D A	-0.87	-0.56	0.63	0.86	0.92	-0.87	0.86	0.15	0.92	0.72	-0.96	-0.92	-0.15	-0.96	-0.57	-0.96	-0.96	0.95	0.63	0.87	-0.94	-0.92	0.91	-0.94	0.61

Click cells to compare fundamentals

Inozyme Pharma Account Relationship Matchups

Inozyme Pharma fundamentals Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Ptb Ratio	3.05	1.47	0.33	1.57	1.41	1.49
Book Value Per Share	6.76	4.64	3.14	2.71	2.44	1.89
Free Cash Flow Yield	(0.0757)	(0.3)	(1.47)	(0.32)	(0.37)	(0.39)
Operating Cash Flow Per Share	(1.54)	(2.04)	(1.53)	(1.36)	(1.57)	(1.65)
Capex To Depreciation	2.62	0.59	0.55	0.36	0.41	0.39
Pb Ratio	3.05	1.47	0.33	1.57	1.41	1.49
Free Cash Flow Per Share	(1.56)	(2.06)	(1.54)	(1.37)	(1.57)	(1.65)
Roic	(0.44)	(0.35)	(0.5)	(0.53)	(0.4)	(0.49)
Payables Turnover	0.0707	0.44	0.46	1.11	1.0	1.05
Cash Per Share	11.95	4.75	3.39	3.64	4.18	5.45
Pocfratio	(13.42)	(3.34)	(0.69)	(3.12)	(2.81)	(2.95)
Capex To Operating Cash Flow	(0.0158)	(0.008245)	(0.007098)	(0.004216)	(0.003795)	(0.003985)
Pfcf Ratio	(13.21)	(3.31)	(0.68)	(3.11)	(2.8)	(2.94)
Days Payables Outstanding	5.2K	830.62	788.92	328.89	378.23	359.32
Income Quality	0.64	0.85	0.86	0.99	1.14	1.03
Roe	0.56	(0.35)	(0.52)	(0.55)	(0.51)	(0.58)
Ev To Operating Cash Flow	(9.01)	(2.92)	(0.23)	(3.29)	(2.97)	(3.11)
Pe Ratio	(8.64)	(2.85)	(0.61)	(3.1)	(2.79)	(2.93)
Return On Tangible Assets	(0.33)	(0.46)	(0.47)	(0.35)	(0.41)	(0.43)
Ev To Free Cash Flow	(8.87)	(2.9)	(0.23)	(3.28)	(2.95)	(3.1)
Earnings Yield	(0.12)	(0.35)	(1.65)	(0.32)	(0.37)	(0.39)
Net Debt To E B I T D A	1.53	2.79	0.36	0.4	(0.16)	(0.18)
Current Ratio	15.14	9.92	8.93	13.36	15.37	14.69
Tangible Book Value Per Share	6.76	4.64	3.14	2.71	2.44	1.89
Graham Number	19.06	15.81	11.07	9.15	8.23	8.79
Shareholders Equity Per Share	6.76	4.64	3.14	2.71	2.44	1.89
Capex Per Share	0.0243	0.0169	0.0109	0.005749	0.006611	0.00628
Graham Net Net	11.21	4.14	2.84	2.48	2.23	2.33
Enterprise Value Over E B I T D A	(5.7)	(2.51)	(0.21)	(3.11)	(2.8)	(2.94)
Price Earnings Ratio	(8.64)	(2.85)	(0.61)	(3.1)	(2.79)	(2.93)
Price Book Value Ratio	3.05	1.47	0.33	1.57	1.41	1.49
Days Of Payables Outstanding	5.2K	830.62	788.92	328.89	378.23	359.32

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GM	General Motors
S	SentinelOne

Additional Tools for Inozyme Stock Analysis

When running Inozyme Pharma's price analysis, check to measure Inozyme Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme Pharma is operating at the current time. Most of Inozyme Pharma's value examination focuses on studying past and present price action to predict the probability of Inozyme Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme Pharma's price. Additionally, you may evaluate how the addition of Inozyme Pharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

Inozyme Historical Financial Ratios

About Inozyme Financial Ratios Analysis

Inozyme Pharma Financial Ratios Chart

Payables Turnover

Income Quality

Inozyme Pharma fundamentals Correlations

Inozyme Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Inozyme Pharma fundamentals Accounts

Also Currently Popular

Additional Tools for Inozyme Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Pb Ratio	+ 1.0	Ptb Ratio
Earnings Yield	+ 1.0	Free Cash Flow Yield
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Days Payables Outstanding	+ 1.0	Capex To Depreciation
Pfcf Ratio	+ 1.0	Pocfratio
Ev To Operating Cash Flow	+ 1.0	Pocfratio

Ev To Free Cash Flow	- 0.99	Days Payables Outstanding
Pe Ratio	- 0.99	Days Payables Outstanding
Ev To Operating Cash Flow	- 0.99	Days Payables Outstanding
Days Payables Outstanding	- 0.99	Pfcf Ratio
Days Payables Outstanding	- 0.99	Capex To Operating Cash Flow
Days Payables Outstanding	- 0.99	Pocfratio